A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer.

Trial Profile

A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Capecitabine; Sorafenib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TIES
  • Most Recent Events

    • 05 Jun 2010 Results of a multivariate analysis investigating the effects of imbalances in prognostic factors between the study arms on the primary endpoint were presented at ASCO 2010.
    • 21 May 2010 Results will be presented at the 2010 ASCO Annual Meeting, according to an Onyx Pharmaceuticals media release.
    • 22 Jul 2009 Primary endpoint 'Progression free survival' has been met, according to an Onyx Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top